Drug Profile
FDL 176
Alternative Names: FDL176Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Flatley Discovery Lab
- Class
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for phase-I development in Cystic-fibrosis(In volunteers) in United Kingdom (PO)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Cystic-fibrosis in Australia (PO)
- 05 Feb 2020 Flatley Discovery Lab suspends a phase I/II trial for Cystic fibrosis (In volunteers) in United Kingdom (NCT03756922)